Bone Biologics (BBLG) Long-Term Deferred Tax (2020 - 2022)

Bone Biologics (BBLG) has 3 years of Long-Term Deferred Tax data on file, last reported at $20.4 million in Q4 2022.

• Long-Term Deferred Tax for Q4 2022 came in at $20.4 million, up 8.3% year-over-year; the trailing twelve-month figure through Dec 2022 was $20.4 million (up 8.3% YoY), and the FY2022 annual result was $20.4 million, up 8.3% from the prior year.
• Long-Term Deferred Tax rose to $20.4 million in Q4 2022 per BBLG's latest filing, from $18.8 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $20.4 million in Q4 2022 and troughed at $18.3 million in Q4 2020.
• A 3-year average of $19.2 million and a median of $18.8 million in 2021 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2021 and 2022: Long-Term Deferred Tax advanced 2.43% in 2021, then advanced 8.3% in 2022.
• A 3-year view of Long-Term Deferred Tax shows it stood at $18.3 million in 2020, then gained by 2.43% to $18.8 million in 2021, then advanced by 8.3% to $20.4 million in 2022.
• Business Quant data shows BBLG's Long-Term Deferred Tax at $20.4 million in Q4 2022, $18.8 million in Q4 2021, and $18.3 million in Q4 2020.